WuXi PharmaTech’s subsidiary, Shanghai SynTheAll (STA) Pharmaceutical Co., has entered into a supply agreement with Pharmacyclics, Inc. This follows a successful development and clinical manufacturing partnership for Pharmacyclics expedited NDA and FDA approval for Imbruvica for the treatment of patients with mantle cell lymphoma. The FDA conducted a GMP pre-approval inspection of WuXi’s manufacturing facilities in August, with no Form 483 observations.   Imbruvica is an oral therapy...